APRE Stock Summary and Trading Ideas (Aprea Therapeutics | NASDAQ:APRE)

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Aprea Therapeutics trades on the NASDAQ stock market under the symbol APRE.

As of February 5, 2026, APRE stock price was flat at $0.67 with 16,614 million shares trading.

APRE has a beta of 2.22, meaning it tends to be more sensitive to market movements. APRE has a correlation of 0.34 to the broad based SPY ETF.

APRE has a market cap of $4.69 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, APRE traded as high as $11.18 and as low as $.47.

The top ETF exchange traded funds that APRE belongs to (by Net Assets): VXF.

APRE has underperformed the market in the last year with a price return of -82.8% while the SPY ETF gained +13.9%. APRE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -51.1% and -19.5%, respectively, while the SPY returned +0.7% and -1.1%, respectively.

APRE support price is $.62 and resistance is $.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APRE shares will trade within this expected range on the day.